Project Grant R01DK136462

Award Date 8/19/24
Completion Date 6/30/28
Dollars Obligated $1.4M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $934,946 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Virginia Commonwealth University (VCU). The grant supports research to investigate the role of the acid ceramidase-sphingosine-1-phosphate (AC-S1P) pathway in the kidney's regulation of sodium excretion and its potential contribution to salt-sensitive hypertension. Specifically, the research...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $115,500 to Wayne State University to conduct research on the molecular mechanisms by which high-salt diets regulate the activity of the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the kidney. The research aims to identify novel E3 ubiquitin...
This federal Project Grant award, totaling $2,158,428 and funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at investigating the role of the glycolytic enzyme pyruvate kinase M2 (PKM2) in mediating hypertension and vascular remodeling. The award supports three specific aims: 1) Studying the involvement of PKM2 activation in vascular smooth muscle cells (VSMCs) in hypertension and vascular...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $114,180.00 to the Regents of the University of Minnesota to conduct research on renal afferent nerve circuitry and its influence on blood pressure regulation. The project aims to 1) elucidate the central terminations and regional specificity of renal afferents, and 2) identify...
This federal Project Grant award of $293,128 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research will support research by The Johns Hopkins University to uncover the role of the G-protein coupled receptor GPR39 in kidney physiology. The research aims to examine the mechanisms by which GPR39 activation influences water reabsorption in the kidney and determine the physiologic function of...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) will provide $596,345 to Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to investigate the molecular mechanisms underlying diabetic renal hypertrophy and its impact on acute kidney injury (AKI) susceptibility and severity in diabetes. The key objectives are to: (1) determine...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,236 to The University of Iowa to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The goal is to evaluate how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium concentration, plasma osmolality, regional sympathetic...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will fund the development of genetically encoded chloride sensors to measure sodium-chloride transport in the kidneys of live mice. The $400,820 award will enable researchers at Wayne State University to generate transgenic mouse models expressing chloride-sensing probes. This will allow them to...
This $194,380 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to study the role of the protein LIM-nebulette in helping podocytes (kidney cells) adapt to mechanical stress, such as that caused by severe hypertension. The grantee, Icahn School of Medicine at Mount Sinai, will use a novel mechanical stretch platform and high-content image analysis to understand how...
This federal Project Grant award of $671,986 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research to strengthen the evidence-base for medication prescribing in older adults with chronic kidney disease (CKD). The primary objectives are to: 1) Evaluate the effectiveness of renoprotective therapies, such as angiotensin converting enzyme inhibitors (ACEIs) and sodium-glucose...

This Project Grant award of $1,357,132.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will fund research conducted by the University of Texas Health Science Center at Houston (UTHealth) to investigate the role of EPAC signaling in regulating renal sodium handling and hypertension. The research aims to:

  1. Determine the salt-sensitivity associated with EPAC-induced changes on tubular transport in mice lacking EPAC isoforms.
  2. Examine the molecular targets and signaling mechanisms of EPAC-dependent regulation of sodium transport in the proximal tubule and collecting duct.
  3. Test the hypothesis that EPAC1 and EPAC2 are effective therapeutic targets for hypertension using optimized EPAC-specific inhibitors.

The goal is to uncover previously unrecognized physiologically relevant mechanisms of EPAC signaling in the kidney and establish the pharmacological potential of EPAC blockade for treating hypertension. The award period runs from August 19, 2024 to June 30, 2028.

Generated 8/5/25, 4:20 AM